| Date | Title | Description |
| 11.09.2024 | Viatris' Tender Offers: A Strategic Move in the Financial Landscape | In the world of finance, timing is everything. Viatris Inc., a global healthcare giant, recently made headlines with its announcement regarding cash tender offers for its outstanding senior notes. This strategic maneuver, aimed at optimizin... |
| 10.09.2024 | Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers | PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers&quo... |
| 10.09.2024 | Viatris Announces Expiration and Results of Any and All Cash Tender Offers | PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an ... |
| 04.09.2024 | Viatris Announces Cash Tender Offers for Certain Outstanding Notes | PITTSBURGH, Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acq... |
| 03.09.2024 | General Anesthesia Drugs Market: Trends, Segmentation, and Future Outlook | Share
Tweet
Share
Share
Email
The global general anesthesia drugs market has been experiencing significant evolution, driven by advancements in medical technology, increasing surgical procedures, and a growing emphasis on patient safety and... |
| 30.05.2024 | US, UK in focus as pharma companies eye $31 billion exports in FY25 | - |
| 15.05.2024 | Fewer U.S., Indiana overdose deaths reported last year, but experts cautious | - |
| 03.05.2024 | Patients on hunt for diabetes, obesity and weight-loss drugs | - |
| 27.04.2024 | India becoming attractive for clinical trials, says pharma industry leaders | - |
| 24.04.2024 | Pharma exports rise around 10% to $27.9 billion, US biggest importer | - |
| 15.04.2024 | Women of Influence: Health Care 2024 – Ileana Hernandez | - |
| 13.03.2024 | После вмешательства генпрокурора РФ 68 южноуральцев обеспечены лекарствами | - |
| 13.03.2024 | Pregabalin Market to Reach $2.2Billion Globally, By 2032 at 3% CAGR: Allied Market Research | - |
| 06.03.2024 | Capecitabine Global Market Report 2024 | - |
| 04.03.2024 | Allergy Immunotherapy Market Demand Analysis and Opportunity Outlook 2030|Adamis Pharmaceuticals,HollisterStier Allergy | Allergy Immunotherapy
Allergy Immunotherapy Market Review: All Eyes on 2024 Outlook
Stay up to date with Allergy Immunotherapy Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.”
—... |
| 23.06.2021 | Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action | |
| 06.11.2020 | Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. | |
| 02.11.2020 | Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris | |
| 08.09.2020 | Mylan to Acquire Aspen's Thrombosis Business in Europe | |
| 31.08.2020 | Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes | |
| 28.07.2020 | PFIZER, INC.
Pfizer : Reports Second-Quarter 2020 Results | Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2020, increased its 2020 financial guidance for revenues and Adjusted diluted EPS(3) and reaffirmed all other components of its 2020 financial guidance, which continues t... |
| 07.09.2018 | Does a generic EpiPen mean lower prices? Don’t hold your breath | You could almost hear the sigh of relief from patients when the FDA earlier this month approved Teva Pharmaceutical’s application to market the first generic versions of EpiPen and EpiPen Jr. in the U.S.
That decision came at the end of a w... |
| 08.08.2018 | A drug priced out of reach in Africa could save lives from a neglected killer | When it comes to controlling the AIDS pandemic, Botswana is in many ways a model for the world. Last year, the country became one of the first to achieve ambitious United Nations goals for universal access to timely, high-quality treatment ... |
| 16.06.2017 | Is Mylan’s EpiPen reign finally over? | Mylan and EpiPens became the face of ‘price gouging.’ Public outcry ensued, along with a dedicated hearing before the House Oversight and Government Reform Committee.
In 2017, the winds are finally shifting.
On Thursday, San Diego, Californ... |
| 17.12.2016 | Mylan launches cheaper version of EpiPen allergy treatment — that costs $300 | Mylan is releasing a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew scorn from parents nationwide and spawned Congressional inquiries.
The potential cost savings wil... |
| 02.09.2016 | NYC comptroller blasts Mylan’s board for ‘weak oversight’ and hurting shareholders | The withering scrutiny given to EpiPen pricing is now extending to the Mylan Pharmaceuticals board of directors and its oversight of the drug maker’s executive team.
In a harshly worded letter sent Thursday, New York City Comptroller Scott ... |
| 25.08.2016 | Under fire, Mylan takes steps to make $600 EpiPen more affordable | In the face of withering criticism, Mylan Pharmaceuticals took steps Thursday to make its EpiPen device more affordable. Specifically, the company is increasing the amount of money on a copay assistance card from $100 to $300, and is also w... |
| 14.07.2014 | Abbott to deal pharma line to Mylan for $5.3B | Mylan (NSDQ:MYL) said today that it agreed to pay $5.3 billion to Abbott (NYSE:ABT) for its non-U.S. developed markets specialty and branded generics business in an all-stock deal.
Once consummated, the deal would see Abbott receive 105 mil... |
| 20.03.2012 | Generic Boniva looms but deal gives GSK new piece of osteoporosis market | Osteoporosis drug Boniva, a GlaxoSmithKline (NYSE:GSK) and Roche (OTC:RHHBY) product, will soon face its first generic competitors.
Mylan (NASDAQ:MYL), Apotex and Orchid Healthcare all received U.S. Food and Drug Administration approval on ... |
| 12.09.2011 | GSK sues to block generic BPH drugs from Mylan, Impax | Avodart’s 2010 sales eclipsed $900 million for London-based GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina. The drug was approved by the FDA in 2001 to treat patients with symptomatic benign prostatic hyperpl... |
| 02.03.2010 | Mylan receives FDA approval for generic gallstones medication | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| 15.08.2008 | Famy Care Plans To Dilute 15% Stake; In Talks With Mylan, PE Funds | Famy Care Ltd, the world’s largest contraceptive pill maker, is in talks with world’s third-largest generic drug maker Mylan Inc and some private equity funds to dilute upto 15 per cent stake. Mumbai-based Famy Care had recently signed a st... |
| - | Is Mylan’s EpiPen reign finally over? | Mylan CEO Heather Bresch testifies before the House Oversight and Government Reform Committee during a 2016 hearing titled “Reviewing the rising price of EpiPens.”
EpiPens save lives. It’s a fact that many patients believe was exploited by ... |
| - | Mylan receives FDA approval for generic gallstones medication | Generic drugmaker Mylan Pharmaceuticals Inc. has received FDA approval to begin shipping a generic version of a drug that treats gallstones.
Ursodial USP is the generic version of Watson Pharmaceuticals’ Actigall capsules. A number of other... |
| - | Generic Boniva looms but deal gives GSK new piece of osteoporosis market | Osteoporosis drug Boniva, a GlaxoSmithKline (NYSE:GSK) and Roche (OTC:RHHBY) product, will soon face its first generic competitors.
Mylan (NASDAQ:MYL), Apotex and Orchid Healthcare all received U.S. Food and Drug Administration approval on ... |
| - | Shire agrees to more clinical trials for blood pressure drug, but threat of FDA action lingers | One year after Shire (NASDAQ:SHPGY) pulled its drug for low blood pressure, ProAmatine, from the market after reaching an impasse with the U.S. Food and Drug Administration, it has agreed to do the additional clinical tests the regulator wa... |
| - | GSK sues to block generic BPH drugs from Mylan, Impax | GlaxoSmithKline (NYSE:GSK) is taking two drug companies to court claiming that their efforts to launch generic versions of enlarged prostate drugs Avodart and Jalyn infringe on GSK patents.
GSK said in the suit that abbreviated new drug app... |
